TD Cowen raised the firm’s price target on BeOne Medicines (ONC) to $360 from $334 and keeps a Buy rating on the shares. The firm notes Q2 Brukinsa beat with $950M. GAAP profitability from beats for tisle and Amgen (AMGN) products plus tight OpEx control.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- BeOne Medicines Reports Strong Q2 2025 Performance
- BeiGene’s Earnings Call Highlights Robust Growth and Market Leadership
- BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target
- BeOne Medicines narrows FY25 revenue view to $5.0B-$5.3B from $4.9B-$5.3B